Human Milk for the Premature Infant

Mark A. Underwood, MD, MAS

KEYWORDS

- Human milk  •  Premature infant  •  Necrotizing enterocolitis  •  Donor milk  •  Lactation

KEY POINTS

- Fortified mother’s own milk is the optimal diet for the premature infant to maximize growth, development, and protection against necrotizing enterocolitis and infection.
- Fortified pasteurized human donor milk is recommended by the American Academy of Pediatrics Section on Breastfeeding as the preferred alternative for premature infants whose mothers are unable to provide a sufficient volume of their own milk.
- Pasteurized donor human milk does not provide the same nutrient or biologically active molecules as unpasteurized own mother’s milk.
- Careful attention to establishing and maintaining milk production in women delivering preterm has significant benefits.

Human milk provides the optimal nutrition for term infants. Human milk is also recommended for preterm infants, but does not alone provide optimal nutrition. The growth and neurodevelopmental needs of the evolutionarily new population of very premature infants are best met by appropriate fortification of human milk. To explore the role of human milk in the care of premature infants, it is appropriate to begin with a comparison of amniotic fluid (the optimal beverage of the fetus), milk from mothers delivering preterm, and milk from mothers delivering at term. We then consider the benefits and challenges of providing human milk to premature infants, approaches to human milk fortification, the advantages and challenges of donor human milk products, and finally some practical approaches to increasing human milk consumption in premature infants.

In the United States, approximately 12% of infants are born preterm (<37 weeks gestation).¹ This is a very heterogeneous population with widely diverse nutritional
requirements and highly different stages of immunocompetence. A 2.5-kg neonate born at 34 weeks gestation differs from a 500-g neonate born at 24 weeks gestation in essentially every physiologic aspect of the gastrointestinal system and the innate and adaptive immune systems. Consequently, the current body of knowledge about nutrition and host defense of premature infants has many gaps. Studies performed on larger, older premature infants may not be applicable to the extremely low birth weight infants (<1000 g) that now survive routinely.

**AMNIOTIC FLUID, “PREMATURE” HUMAN MILK, AND “TERM” HUMAN MILK**

Amniotic fluid contains amino acids, proteins, vitamins, minerals, hormones, and growth factors. Although the concentration of these nutrients is much lower than that found in human milk, the large volumes of amniotic fluid swallowed in utero (up to 1 liter a day late in gestation, considerably more than the newborn consumes after birth) have a significant impact on growth and maturation of both the fetus and the fetal intestine. Animal studies and limited human observations suggest that swallowed amniotic fluid accounts for about 15% of fetal growth.

Milk from women who deliver prematurely differs from that of women who deliver at term. Preterm milk is initially higher in protein, fat, free amino acids, and sodium, but over the first few weeks following delivery these levels decrease. The mineral content (including trace minerals) of preterm milk is similar to that of term milk, with the following exceptions: Calcium is significantly lower in preterm milk than term milk and does not seem to increase over time, whereas copper and zinc content are both higher in preterm milk than term milk and decrease over the time of lactation.

Lactose is the major carbohydrate in human milk. This disaccharide is an important energy source, is relatively low in colostrum, and increases over time with more dramatic increases in preterm milk. Complex oligosaccharides are the second most abundant carbohydrate in human milk. These human milk oligosaccharides (HMOs) are not digestible by host glycosidases and yet are produced in large amounts with highly variable structures by the mother. HMOs seem to have 3 important functions: Prebiotic (stimulation of commensal bacteria containing the bacterial glycosidases to deconstruct and consume the HMOs), decoy (structural similarity to the glycans on enterocytes allows HMOs to competitively bind to pathogens), and provision of fucose and sialic acid, which seem to be important in host defense and neurodevelopment, respectively. Preterm milk is highly variable in HMO content with differences between populations and significant variability over time in content of fucosylated HMOs in individual mothers delivering preterm. Glycosaminoglycans also seem to act as decoys, providing binding sites for pathogenic bacteria to prevent adherence to the enterocyte. Premature milk is richer in glycosaminoglycans than term milk.

Bioactive molecules in human milk are important components of the innate immune system. Differences in cytokines, growth factors, and lactoferrin between preterm and term milk are most dramatic in colostrum and early milk and mostly resolve by 4 weeks after delivery. Leptin is produced by mammary glands, secreted into human milk, and may be important in post-natal growth. Human milk leptin does not seem to differ between preterm and term milk. Bile salt-stimulated lipase activity is similar in term and preterm milk, whereas lipoprotein lipase activity is higher in term milk.

**BENEFITS OF HUMAN MILK FOR PREMATURE INFANTS**

The most recent policy statement from the Section on Breastfeeding of the American Academy of Pediatrics represents a significant shift from previous statements in its
Fig. 1. Changes in milk composition over time in term (FT, 37–41 weeks), preterm (PT, 30–36 weeks), and very preterm (VPT, <28–30 weeks) infants. Nutrients (A); Bioactive molecules (B). EGF, epidermal growth factor; GAG, glycosaminoglycans; IL-6, interleukin 6; IgA, immunoglobulin A; IL-10, interleukin 10; TNF-alpha, tumor necrosis factor alpha. (Data from Refs. 15,82,115–122)
recommendation that all preterm infants should receive human milk, with pasteurized donor milk rather than premature infant formula the preferred alternative if a mother is unable to provide an adequate volume. The current recommendation is based on an impressive array of benefits that human milk provides to this highly vulnerable population, including decreased rates of late-onset sepsis, necrotizing enterocolitis (NEC), and retinopathy of prematurity; fewer re-hospitalizations in the first year of life, and improved neurodevelopmental outcomes. In addition, premature infants who receive human milk have lower rates of metabolic syndrome, lower blood pressure and low-density lipoprotein levels, and less insulin and leptin resistance when they reach adolescence, compared with premature infants receiving formula.

Among these benefits, perhaps the most compelling benefit of human milk feeding is the observed decrease in NEC, given its high prevalence (5%–10% of all infants with birth weight <1500 g), high case fatality, and long-term morbidity owing to complications like strictures, cholestasis, short-bowel syndrome, and poor growth and neurodevelopment. For many of these outcomes, there seems to be a dose response effect of human milk feeding. For instance, a dose of mother’s own milk of more than 50 mL/kg per day decreases the risk of late-onset sepsis and NEC compared with less than 50 mL/kg per day, and for each 10 mL/kg per day increase in human milk in the diet there is a 5% reduction in hospital readmission rate. The mechanisms by which human milk protects the premature infant against NEC are likely multifactorial. Human milk secretory immunoglobulin A, lactoferrin, lysozyme, bile salt-stimulating lipase, growth factors, and HMOs all provide protective benefits that could potentially contribute to reduction in NEC. In a multicenter, randomized clinical trial, bovine lactoferrin treatment decreased late-onset sepsis but not NEC in premature infants. Recombinant human lactoferrin trials are currently in progress in premature infants. In animal models, epidermal growth factor and pooled HMOs prevent NEC, but these have not yet been tested in premature infants.

Microbial colonization is thought to play an important role in risk of NEC. Breast-feeding is one of many factors that influence the composition of the intestinal microbiota in term infants; limited studies suggest that diet may have less of an effect on the composition of the intestinal microbiota in the premature infant than other factors (such as antibiotic administration). New bioinformatic tools to correlate the extensive array of fecal metabolites and the fecal microbiota offer great promise in understanding the factors that influence the microbiota of the premature infant. Studies to date suggest that the metabolites differing between human milk-fed and formula-fed infants that are most closely associated with shaping the microbiota include sugars and fatty acids. Whether and how these metabolites differ functionally in the extremely premature infant is unknown.

Other potential benefits of human milk to premature infants have been studied with mixed results. There do not seem to be consistent benefits of human milk in premature infants in relation to feeding tolerance, time to full enteral feeding, or allergic/atopic outcomes. Providing human milk has been postulated to decrease parental anxiety, and increase skin-to-skin contact and parent–infant bonding, but data to support these hypotheses are limited. The provision of human colostrum in the form of oral care for intubated premature infants has been proposed as a method of stimulating the oropharyngeal-associated lymphatic tissue and altering the oral microbiota, but data to support this intervention are lacking.

Studies of the benefits of human milk in premature infants to date have predominantly compared mother’s own milk with premature infant formula. Whether pasteurized donor human milk (which generally is provided by women who delivered at term) provides
similar or superior protection is unclear. In premature infants receiving only mother’s own milk or pasteurized donor human milk (no formula), increasing amounts of mother’s own milk correlate with better weight gain and less NEC. A meta-analysis in 2007 concluded that formula feeding was associated with both increased short-term growth and increased incidence of NEC compared with donor human milk feeding (relative risk, 2.5; 95% confidence interval [CI], 1.2–5.1), number needed to harm 33 (95% CI, 17–100) with no differences in long-term growth or neurodevelopment. However, of the 8 studies included in the meta-analysis, 7 were published before 1990, during which time nutritional comparisons were limited. For example, several of the reviewed studies did not include formulas designed for premature infants and none included nutrient-enriched donor milk. One study, initiated in 1982, followed a cohort of premature infants who received either premature infant formula or unfortified donor human milk with the latter group showing decreased blood pressure and improved lipoprotein profiles as adolescents. In the single included study published since 1990, infants whose mothers were unable to provide sufficient milk for their extremely premature infants (<30 weeks’ gestation) were randomly assigned to receive supplementation with either premature infant formula or nutrient-enriched donor human milk; donor human milk led to slower weight gain, but did not decrease episodes of sepsis, or retinopathy of prematurity, length of hospital stay, or mortality compared with supplementation with premature infant formula. The incidence of NEC was decreased in the donor human milk group by almost half compared with the formula group, but this did not attain significance owing to the small sample size. It is noteworthy in this study that, despite increased supplementation in the donor milk group, 20% of the infants were changed to formula because of poor growth. A more recent comparison of mother’s own milk with pasteurized human donor milk demonstrated improved growth and less NEC with the former.

**CHALLENGES OF PROVIDING HUMAN MILK TO PREMATURE INFANTS**

Providing human milk to very premature infants presents a variety of challenges. To maximize milk supply, new mothers should begin frequent pumping shortly after delivery. Mothers whose babies are in the neonatal intensive care unit (NICU) should be encouraged to begin pumping within 6 to 12 hours of delivery and to pump 8 to 12 times per day, ensuring that they empty the breast each time. These interventions significantly increase the likelihood that a premature infant will receive his mother’s own milk.

Perhaps the greatest concern in providing human milk to premature infants is growth. Term infants undergo rapid growth in the third trimester of pregnancy, receiving nutrition through the placenta and swallowed amniotic fluid with no need to expend calories for temperature regulation or gas exchange. Premature infants miss out on much or all of the third trimester and thus have higher nutritional requirements on a per kilogram basis than term infants. Human milk evolved/was designed to nourish the term infant who can tolerate large fluid volumes, whereas premature infants are less tolerant of high fluid volumes.

For these reasons, human milk is generally fortified for premature infants with birth weights of less than 1500 g. Human milk fortifier powders were developed from bovine milk to supplement key nutrients with particular emphasis on protein, calcium, phosphorus, and vitamin D. Fortification of human milk leads to improved growth in weight, length, and head circumference; however, improvements in bone mineralization and neurodevelopmental outcomes are unclear. Recent studies suggest that higher protein intake is beneficial for premature infants. There is large variation in the
energy and protein content of human milk (between mothers, over time in a given mother, and between foremilk and hindmilk). Protein content decreases over time of lactation and is likely to be much lower in donor human milk than milk from mothers delivering prematurely. Current NICU practices are often based on the clearly misleading assumption that human milk has approximately 0.67 kcal/mL with stable protein content. “Assumed” protein intake from standard fortification is significantly lower than actual protein intake. These observations have led to clinical trials of “individualized” fortification, that is, adjusting the amount of added protein based on actual measurements of milk samples or based on metabolic parameters indicative of protein accretion in the neonate (eg, blood urea nitrogen). Both methods led to increased protein intake and improved growth. A recent trial of a human milk fortifier with higher protein content demonstrated increased growth and fewer infants with weight below the 10th percentile.

Use of commercial human milk fortifiers, however, is not without complications, as demonstrated by the observation of a marked increase in metabolic acidosis associated with the introduction of a new fortifier. Human milk fortifiers have also been associated with increased markers of oxidative stress compared with unfortified human milk and with infant formula. In addition, bacterial contamination of powdered infant formulas and associated sepsis has been well documented, resulting in more than 100 cases of neonatal Cronobacter (Enterobacter sakazakii) infections leading to high mortality rates. This association has led to calls for “powder-free” NICUs and the development of new liquid human milk fortifiers. Unfortunately, one of the challenges of liquid fortifiers is displacement of the volume of mother’s own milk, so that the infant receives less total volume of human milk. Table 1 provides a comparison of the nutrient content and volume of human milk displaced by the liquid formulations of several commercial human milk fortifiers. Note that the use of the bovine liquid fortifiers means that 17% to 50% of the volume ingested is formula. The table also demonstrates the significant variation in macro- and micronutrients among these products.

**PASTEURIZED DONOR HUMAN MILK FOR PREMATURE INFANTS**

There are significant challenges in providing donor human milk for all premature infants whose mothers are unable to provide an adequate supply of their own milk: Nutrition, safety, supply, and immune protection. First, most donor human milk is provided by women who have delivered at term and have weaned their own infant but continue to pump and donate their milk in later lactation. As noted in Fig. 1, this milk from mothers of term infants, several months after delivery, is low in protein, fat, and many bioactive molecules compared with preterm milk provided in the first few weeks after delivery. A second challenge of providing donor milk is to minimize the potential to transmit infectious agents. For this reason, milk banks have rigid standards for screening and testing potential donors, for pasteurization, and for testing milk before distribution. Pasteurization is highly effective at decreasing the risk of transmission of HIV, cytomegalovirus (CMV), hepatitis B, and hepatitis C. The costs involved in establishing and maintaining a milk bank are considerable; however, the feasibility of providing pasteurized donor milk in developing countries has been demonstrated. Unpasteurized donor milk has been advocated for premature infants in areas where religious beliefs preclude the use of milk from unknown donors. Further, “mother-to-mother milk-sharing” through Internet-based communities is a rapidly growing practice in more than 50 countries, but health officials recommend against this practice owing to safety risks, including lack of pasteurization, uncertain
storage and shipping processes, and uncertain medication and substance use in the donor.\textsuperscript{64} Unfortunately, although pasteurization safeguards against transmission of infectious agents, it also has detrimental effects on the bioactive components of human milk. The currently recommended Holder pasteurization method (62.5°C for 30 minutes) results in significant decreases in secretory immunoglobulin A, lactoferrin, lysozyme, insulin-like growth factors, hepatocyte growth factor, water-soluble vitamins, bile salt-stimulated lipase, lipoprotein lipase, and anti-oxidant activity, but does not decrease oligosaccharides, long-chain polyunsaturated fatty acids, gangliosides, lactose, fat-soluble vitamins, or epidermal growth factor.\textsuperscript{65–69} Holder pasteurization increases some medium chain saturated fatty acids, decreases some cytokines (tumor necrosis factor-\(\alpha\), interferon-\(\gamma\), interleukin (IL)-1\(\beta\), and IL-10), and increases others (IL-8).\textsuperscript{70} High-temperature, short-time pasteurization (72°C–75°C for 15–16 seconds) has been demonstrated to eliminate bacteria and many viruses\textsuperscript{71,72} with less protein loss (including maintenance of bile salt stimulating lipase, lactoferrin, and some immunoglobulins),\textsuperscript{73} less severe loss of antioxidant activity, but greater loss of antimicrobial activity.\textsuperscript{66,74} In resource-poor countries, flash-heat treatment (temperature >56°C for 6 minutes 15 seconds) does not alter milk antibacterial activity against \textit{Escherichia coli} and \textit{Staphylococcus aureus}, only minimally decreases lactoferrin antibacterial activity, but significantly diminishes lysozyme antibacterial activity.\textsuperscript{75} Further research to determine the optimal pasteurization method to minimize risk and maximize bioactivity has great potential benefit for premature infants.

A fundamental concern is that the supply of donor human milk is currently limited. There are 12 milk banks in the United States and Canada that form the Human Milk Banking Association of North America (www.hmbana.org). In 2011, Human Milk Banking Association of North America milk banks distributed more than 2 million ounces of donor milk (a 5-fold increase from 2000), and the International Breast Milk Project (www.breastmilkproject.org) has distributed more than 280,000 ounces of donor milk to infants in South Africa since its founding in 2006, but such distributions represent only a fraction of the potential demand. The scarcity of this precious resource raises questions about how to increase the supply and equitably allocate human milk.\textsuperscript{76}

**AN “ALL-HUMAN” DIET FOR PREMATURE INFANTS**

The development of a human milk fortifier formulated by concentrating pasteurized donor human milk and then adding vitamins and minerals has created the possibility of providing an “all-human diet” to premature infants. Various caloric densities of this fortifier allow for individual adjustment based on growth or blood urea nitrogen. A small study demonstrated a decrease in both moderate and severe NEC in small premature infants (birth weight <1250 g) receiving the “all-human diet.”\textsuperscript{77} Unfortunately, this study was not adequately powered to study NEC as an outcome and the comparison group received formula if mother’s milk supply was not adequate, whereas the “all-human” infants received donor human milk in such a situation (ie, the increase in NEC in the comparison group could be related to either the powdered bovine human milk fortifier or the premature infant formula). This study underscores the fundamental question of whether components of human milk are protective against NEC or components of bovine milk somehow induce NEC. These 2 possibilities are, of course, not mutually exclusive. The cost of providing a fortifier made from donor human milk is significant. A recent cost-benefit analysis suggested that the savings in NEC prevention outweigh the costs of the “all-human” strategy; however, this analysis was based
### Table 1
Nutrient content of commonly used human milk fortifiers in North America

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Enfamil Human Milk Fortifier Acidified Liquid (4 Vials = 20 mL) Add to 100 mL EBM</th>
<th>Similac Special Care 30 Cal/oz (50 mL) Add to 50 mL EBM</th>
<th>Prolact +4 H₂MF (20 mL) Add to 80 mL EBM</th>
<th>Similac Human Milk Fortifier (4 Packets = 3.6 g) Add to 100 mL EBM</th>
<th>Enfamil Human Milk Fortifier (4 Packets = 2.8 g) Add to 100 mL EBM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein source</td>
<td>Bovine</td>
<td>Bovine</td>
<td>Powder</td>
<td>Bovine</td>
<td>Bovine</td>
</tr>
<tr>
<td>Calories (g)</td>
<td>30</td>
<td>50</td>
<td>28</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>Protein (g)</td>
<td>2.2</td>
<td>1.5</td>
<td>1.2</td>
<td>1.0</td>
<td>1.1</td>
</tr>
<tr>
<td>Fat (g)</td>
<td>2.3</td>
<td>3.3</td>
<td>1.8</td>
<td>0.36</td>
<td>1</td>
</tr>
<tr>
<td>Carbohydrate (g)</td>
<td>&lt;1.2</td>
<td>3.9</td>
<td>1.8</td>
<td>1.8</td>
<td>&lt;0.4</td>
</tr>
<tr>
<td>Vitamin A (IU)</td>
<td>1160</td>
<td>625</td>
<td>61</td>
<td>620</td>
<td>950</td>
</tr>
<tr>
<td>Vitamin D (IU)</td>
<td>188</td>
<td>75</td>
<td>26</td>
<td>120</td>
<td>150</td>
</tr>
<tr>
<td>Vitamin E (IU)</td>
<td>5.6</td>
<td>2.0</td>
<td>0.4</td>
<td>3.2</td>
<td>4.6</td>
</tr>
<tr>
<td>Vitamin K (µg)</td>
<td>5.7</td>
<td>6.0</td>
<td>&lt;0.2</td>
<td>8.3</td>
<td>4.4</td>
</tr>
<tr>
<td>Vitamin B1 (µg)</td>
<td>184</td>
<td>125</td>
<td>4</td>
<td>233</td>
<td>150</td>
</tr>
<tr>
<td>Vitamin B2 (µg)</td>
<td>260</td>
<td>310</td>
<td>15</td>
<td>417</td>
<td>220</td>
</tr>
<tr>
<td>Vitamin B6 (µg)</td>
<td>140</td>
<td>125</td>
<td>4.1</td>
<td>211</td>
<td>115</td>
</tr>
<tr>
<td>----------------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>Vitamin B12 (µg)</td>
<td>0.64</td>
<td>0.27</td>
<td>0.05</td>
<td>0.64</td>
<td>0.18</td>
</tr>
<tr>
<td>Niacin (µg)</td>
<td>3700</td>
<td>2500</td>
<td>52.4</td>
<td>3570</td>
<td>3000</td>
</tr>
<tr>
<td>Folic acid (µg)</td>
<td>31</td>
<td>18.5</td>
<td>5.4</td>
<td>23</td>
<td>25</td>
</tr>
<tr>
<td>Pantothenic acid (µg)</td>
<td>920</td>
<td>950</td>
<td>74.8</td>
<td>1500</td>
<td>730</td>
</tr>
<tr>
<td>Biotin (µg)</td>
<td>3.4</td>
<td>18.5</td>
<td>Not available</td>
<td>26</td>
<td>2.7</td>
</tr>
<tr>
<td>Vitamin C (mg)</td>
<td>15.2</td>
<td>18.5</td>
<td>&lt;0.2</td>
<td>25</td>
<td>12</td>
</tr>
<tr>
<td>Calcium (mg)</td>
<td>116</td>
<td>90</td>
<td>103</td>
<td>117</td>
<td>90</td>
</tr>
<tr>
<td>Phosphorus (mg)</td>
<td>63</td>
<td>50</td>
<td>53.8</td>
<td>67</td>
<td>50</td>
</tr>
<tr>
<td>Iron (mg)</td>
<td>1.76</td>
<td>0.9</td>
<td>0.1</td>
<td>0.35</td>
<td>1.44</td>
</tr>
<tr>
<td>Zinc (mg)</td>
<td>0.96</td>
<td>0.75</td>
<td>0.7</td>
<td>1.0</td>
<td>0.72</td>
</tr>
<tr>
<td>Copper (µg)</td>
<td>60</td>
<td>125</td>
<td>64</td>
<td>170</td>
<td>44</td>
</tr>
<tr>
<td>Manganese (µg)</td>
<td>10</td>
<td>6</td>
<td>&lt;12</td>
<td>7.2</td>
<td>10</td>
</tr>
<tr>
<td>Sodium (mg)</td>
<td>27</td>
<td>22</td>
<td>37</td>
<td>15</td>
<td>16</td>
</tr>
<tr>
<td>Potassium (mg)</td>
<td>45</td>
<td>65</td>
<td>50</td>
<td>63</td>
<td>29</td>
</tr>
<tr>
<td>Chloride (mg)</td>
<td>28</td>
<td>41</td>
<td>29</td>
<td>38</td>
<td>13</td>
</tr>
</tbody>
</table>

*Abbreviation:* EBM, expressed breast milk.

* Values are averages and may vary.
on assumptions generated from the clinical trial described and may therefore overes-
imate the protective effect of this approach.\textsuperscript{78} The ethical issues of marketing human
milk for profit have recently been reviewed.\textsuperscript{76}

**IMPROVING BREASTFEEDING RATES FOR PREMATURE INFANTS**

Premature labor and delivery are highly stressful to parents. Education regarding the
importance and value of breastfeeding should begin during pregnancy and be reem-
phasized when premature delivery seems likely. As noted, pumping with an electric
pump should be initiated within 6 to 12 hours of delivery and continued 8 to 12 times
per 24 hours until the milk supply is well established.\textsuperscript{45} Reassurance and encour-
agement are valuable, because new mothers are often worried and discouraged by the
initial small volumes obtained. Early assistance by a nurse or lactation consultant is
helpful in establishing an effective pumping regimen. Regular questioning by the
NICU nurse or physician regarding milk supply is valuable to encourage early interven-
tion when milk production decreases. Milk production decreases with maternal
depression and increases with increased frequency of pumping and time spent
skin-to-skin with the premature infant.\textsuperscript{79}

Parents should be instructed in the proper labeling, storage, and transport of milk so
that milk pumped at home arrives frozen in the NICU. Color-coded labeling of colos-
trum to ensure its early/immediate use is valuable. A recent study demonstrated
that fresh human milk is stable in a 4°C refrigerator for 96 hours and does not need
to be discarded after 24 or 72 hours as previously practiced.\textsuperscript{80} Freezing and thawing
of human milk may rupture fat globules, leading to adherence of lipid to plastic
surfaces. For this reason, there may be benefit in avoiding continuous feedings of
human milk when possible and positioning syringe pumps so that the syringe is near
vertical.\textsuperscript{81}

Differences in nutrient content between foremilk and hindmilk are well established.
Hindmilk from women delivering preterm is higher in protein, fatty acids, energy, and
fat-soluble vitamins than foremilk.\textsuperscript{82,83} The practice of discarding the foremilk and
feeding premature infants predominantly hindmilk has been shown to increase weight
gain.\textsuperscript{84,85} Hindmilk has higher viscosity and may be more difficult to express with an
electric pump. The combination of hand expression and electric pumping has been
shown to increase milk production\textsuperscript{86} and fat content of expressed milk.\textsuperscript{87} The benefits
of increased hindmilk include not only increased calories, but increased polysaturated fats and increased absorption of fat-soluble vitamins.

It is common for women delivering prematurely to experience a decrease in milk
production. Interventions to increase production include increased skin-to-skin
time, stress reduction, careful attention to diet, sleep, and pumping schedule, and
medications.\textsuperscript{88} Domperidone is effective in increasing milk production.\textsuperscript{89,90} Metoclo-
promide has also been studied as a galactogogue; however, studies to date are of
limited quality and enthusiasm for this product is dampened by concerns about tardive
dyskinesia. Herbal galactagogues are popular, with more than 15% of lactating
women reporting use. Fenugreek (*Trigonella foenumgraecum*) is widely used with
several anecdotal reports of increased milk supply within 24 to 72 hours in most
women.\textsuperscript{91} Two small, randomized, blinded, placebo-controlled trials are available in
the medical literature. The first showed no difference in milk supply in women receiving
capsules of fenugreek compared with the reference group.\textsuperscript{92} The second showed an
increase in milk production of almost double in women receiving tea containing fenu-
greek, fennel, raspberry leaf, and goat’s rue compared with a placebo tea.\textsuperscript{93} Maternal
side effects include nausea, diarrhea, and exacerbation of asthma. Because
fenugreek is a member of the pea family, mothers allergic to chickpeas, soybeans, or peanuts should avoid this remedy. It is worth noting that fenugreek can impart a maple syrup odor to the sweat and urine of both mother and infant. Studies of milk composition and amount of fenugreek in expressed milk have not been published. Milk thistle (Silbum marianum) has been demonstrated in a placebo-controlled trial to almost double milk production with no change in nutrient content of the milk or detectable levels of the active ingredient (silymarin). Side effects seem to be rare and include nausea, diarrhea, and anaphylaxis. Shatavari (dried powdered Asparagus racemosus root) has been studied in 2 randomized, placebo-controlled, blinded studies, with 1 study demonstrating increased maternal prolactin levels and increased infant weight gain and the other showing no benefit. Side effects include runny nose, conjunctivitis, and contact dermatitis. Torbangun leaves (Coleus amboinicus Lour) added to a soup increased milk production in a randomized, blinded, placebo-controlled trial; however, side effects were not mentioned and a commercial preparation is not available. Evidence of safety and efficacy of other herbal galactagogues including blessed thistle, fennel, and chasteberry is lacking. Detailed reviews of the existing data for herbal galactagogues are available.

Successful transition from tube feedings to breastfeeding can be challenging. Skin-to-skin care begun as soon as the baby is stable improves hemodynamic stability without increasing energy expenditure. Non-nutritive sucking (mother pumps first and then places the baby to the breast) can be attempted as soon as the baby is extubated and stable with success noted as early as 28 weeks corrected gestational age. Most premature infants can begin nutritive suckling at about 32 weeks gestation. Assistance from an experienced nurse or lactation consultant is invaluable. Positioning that supports the mother’s breast and the baby’s head and neck are essential, with the cross-cradle and football holds being most effective. Early use of nipple shields increases milk intake and duration of breastfeeding.

WITHHOLDING MOTHER’S OWN MILK FROM PREMATURE INFANTS

In most instances, provision of mother’s own milk is optimal. The few circumstances in which mother’s own milk should not be provided are discussed in Chapter 15. Although it is certainly plausible that premature infants with their immature immune systems are more vulnerable to infection, in most cases data regarding differences between premature and term infants in susceptibility to milk-associated infections are lacking. This section focuses on contraindications specific to premature infants.

Post-natal transmission of CMV through breast milk is a frequent occurrence given that approximately 50% of adults are carriers of CMV. Symptomatic post-natal CMV infection is rare in term infants, likely because of maternal antibody transfer in the third trimester. A recent meta-analysis found wide variation among studies with overall mean rate of CMV transmission via breast milk of 23%, a mean risk of symptomatic CMV infection of 3.7%, and a mean risk of sepsis-like symptoms of 0.7% with most symptomatic infections in premature infants. Low birth weight and early transmission after birth are risk factors for symptomatic disease. Whether CMV infection increases the severity of the diseases of prematurity (eg, chronic lung disease, NEC, periventricular leukomalacia) is unknown. Long-term studies of premature infants infected with CMV through mother’s own milk are few, but suggest that hearing loss and severe neurodevelopmental delays are uncommon. Pasteurization inactivates CMV; freezing may decrease but does not eliminate transmission of CMV. There is no consensus among neonatologists and pediatricians regarding the best balance between the benefits of human milk and the risks of CMV infection.
Recommendations vary from pasteurizing all human milk until corrected gestational age of 32 weeks, to screening all mothers who deliver preterm and withholding colostrum and pasteurizing milk of women who are CMV IgG positive, to freezing all CMV-positive milk for premature infants younger than 32 weeks.

Drug abuse is common among pregnant and nursing women and increases the risk of premature delivery.\textsuperscript{107,108} Long-term effects of in utero and post-natal exposure to these substances are unclear, but studies to date are concerning.\textsuperscript{109,110} Whether the risks of continued exposure to these substances outweigh the benefits of human milk for the premature infant with its rapidly developing central nervous system is unclear. Current guidelines are to encourage mothers who abuse substances other than opiates to obtain counseling and to refrain from providing milk for their infants until they are free of the abused drugs.\textsuperscript{111}

Treatment of depression in pregnancy and in breastfeeding women is an area of particular relevance given the reported associations between maternal antidepressant use and preterm labor,\textsuperscript{112} neonatal seizures,\textsuperscript{112} and neonatal primary pulmonary hypertension. Causality and the mechanisms underlying these associations are unknown. It is unclear whether the latter association in a small number of studies is related to the medications or to risk factors associated with both maternal depression and pulmonary hypertension (eg, obesity, smoking, prematurity, and cesarean delivery).\textsuperscript{113} A recent review of antidepressant medication use in lactating women suggested caution in the use of fluoxetine and avoidance of doxepine and nefazodone.\textsuperscript{114} Data specific to preterm infants or neonates with pulmonary hypertension are not available.

It is likely that in situations where mother’s own milk should not be given, donor human milk would be advantageous. There are rare exceptions wherein an infant should receive no (eg, galactosemia) or limited volumes (eg, some inborn errors of metabolism and human milk protein intolerance) of human milk. These are particularly relevant to premature infants in whom the brain is developing rapidly.

SUMMARY

Fortified human milk has tremendous benefits in improving the growth and short- and long-term outcomes for the premature infant. Mother’s own milk has clear advantages to donor human milk both owing to its composition and the lack of necessity for pasteurization. Increased efforts to establish and maintain milk supply in women delivering preterm are likely to have greater benefits than providing pasteurized donor human milk. Improved pasteurization protocols and carefully performed trials of galactagogues may be of particular value to this highly vulnerable population.

ACKNOWLEDGMENTS

The author wishes to thank Sarah Lueders, UC Davis Children’s Hospital NICU dietitian, for assistance in compiling Table 1.

REFERENCES


